-
Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2021 ASP) 2019 or earlier 2019 5.0% 1.1% 2020 2020 2.7% 1.1% 2021 2021 0.7% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2020 ASP) 2018 or earlier 2018 5.9% 3.0% 2019 2019 4.3% 3.0% 2020 2020 2.0% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2019 ASP) 2017 or earlier 2017 5.4% 3.5% 2018 2018 3.9% 3.5% 2019 2019 2.3% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2018 ASP) 2016 or earlier 2016 4.2% 2.4% 2017 2017 3.0% 2.4% 2018 2018 1.6% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2017 ASP) 2015 or earlier 2015 4.5% 2.1% 2016 2016 2.6% 2.1% 2017 2017 1.4% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2016 ASP) 2014 or earlier 2014 4.0% 1.7% 2015 2015 3.1% 1.7% 2016 2016 1.1% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2015 ASP) 2013 or earlier 2013 4.4% 3.0% 2014 2014 2.9% 3.0% 2015 2015 2.0% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2014 ASP) 2012 or earlier 2012 5.4% 1.4% 2013 2013 2.4% 1.4% 2014 2014 0.9% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2013 ASP) 2011 or earlier 2011 4.4% 3.0% 2012 2012 2.9% 3.0% 2013 2013 2.0% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2012 ASP) 2010 or earlier 2010 7.2% 3.0% 2011 2011 4.1% 3.0% 2012 2012 2.0% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2011 ASP) 2009 or earlier 2009 6.4% 3.2% 2010 2010 4.6% – 2011 2011 2.1% –
Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2010 ASP) 2008 or earlier 2008 4.3% 3.3% 2009 2009 3.9% – 2010 2010 2.2% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2009 ASP) 2007 or earlier 2007 4.5% 2.7% 2008 2008 2.1% – 2009 2009 1.8% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2008 ASP) 2006 or earlier 2006 4.9% 0.5% 2007 2007 2.7% – 2008 2008 0.3% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2007 ASP) 2005 or earlier 2005 6.6% 3.6% 2006 2006 4.5% 3.6% 2007 2007 2.4% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2006 ASP) 2004 or earlier 2004 6.5% 3.2% 2005 2005 4.2% 3.2% 2006 2006 2.1% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2005 ASP) 2003 or earlier 2003 6.2% 3.0% 2004 2004 4.3% 3.0% 2005 2005 2.0% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2004 ASP) 2002 or earlier 2002 7.0% 3.3% 2003 2003 4.1% 3.3% 2004 2004 2.2% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2003 ASP) 2001 or earlier 2001 7.0% 2.7% 2002 2002 4.6% 2.7% 2003 2003 1.8% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2002 ASP) 2000 or earlier 2000 7.7% 4.2% 2001 2001 5.1% 4.2% 2002 2002 2.8% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2001 ASP) 1999 or earlier 1999 7.7% 3.5% 2000 2000 4.8% 3.5% 2001 2001 2.3% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 2000 ASP) 1998 or earlier 1998 7.2% 3.8% 1999 1999 5.3% 3.8% 2000 2000 2.5% – Year Introduced
(first sold)Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 1999 ASP) 1997 or earlier 1997 5.5% 4.1% 1998 1998 4.5% 4.1% 1999 1999 2.7% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 1998 ASP) 1996 or earlier 1996 4.9% 2.6% 1997 1997 3.2% 2.6% 1998 1998 2.2% – Year Introduced (first sold) Benchmark Year Allowable Increase over ASP in Benchmark Year PMPRB 1 Year Cap (Allowable Increase over 1997 ASP) 1995 or earlier 1995 5.0% 2.7% 1996 1996 3.4% 2.7% 1997 1997 1.8% – -
PMPRB CPI Guideline
The Patented Medicine Prices Review Board (PMPRB) Guidelines allow the prices of patented medicines to increase by no more than the increase in the Consumer Price Index (CPI) calculated over a 3 year period. In addition, price increases over the previous year are limited to 1.5 times the projected inflation rate of the year in which the increase will take place. The specific wording of the PMPRB’s CPI Guideline is:
- The price of an existing medicine during the period under review will be presumed to be excessive if it exceeds the benchmark price of the DIN adjusted for the cumulative change in the Consumer Price Index (CPI) from the benchmark period to the pricing period under review (CPI Adjusted Price).
- In addition, one year price increases may not exceed 1.5 times the forecast change in the annual CPI.
- In periods of high inflation (over 10%), the limit will be 5 percentage points more than the annual forecast change in the annual CPI.
Important Notes
- The "Year Introduced" refers to the year in which the medicine is first sold in Canada as a patented medicine (with or without a Notice of Compliance).
- The "Benchmark Year" refers to the year to which the Board’s 3 year CPI methodology is applied.
- The "Average Selling Price (ASP) in the Benchmark Year" used in the calculation is the lower of the actual average selling price in that year and the maximum non-excessive (MNE) price for that year as calculated by Board staff.
- The "1 Year Cap" is the maximum 1 year percentage increase allowed over the previous year’s ASP (or MNE price if that is lower).
- All price increases are further constrained by the Board’s International Price Guideline which limits the prices of all patented medicines from exceeding the range of prices in the 7 comparator countries (France, Germany, Italy, Sweden, Switzerland, the United Kingdom, and the United States).
- The official PMPRB CPI Guideline is now available online at www.pmprb-cepmb.gc.ca